Endothelial Dysfunction, Atherosclerosis, and Increase of von Willebrand Factor and Factor VIII: A Randomized Controlled Trial in Swine.
Journal
Thrombosis and haemostasis
ISSN: 2567-689X
Titre abrégé: Thromb Haemost
Pays: Germany
ID NLM: 7608063
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
pubmed:
29
1
2021
medline:
15
12
2021
entrez:
28
1
2021
Statut:
ppublish
Résumé
It is well known that high von Willebrand factor (VWF) and factor VIII (FVIII) levels are associated with an increased risk of cardiovascular disease. It is still debated whether VWF and FVIII are biomarkers of endothelial dysfunction and atherosclerosis or whether they have a direct causative role. Therefore, we aimed to unravel the pathophysiological pathways of increased VWF and FVIII levels associated with cardiovascular risk factors. First, we performed a randomized controlled trial in 34 Göttingen miniswine. Diabetes mellitus (DM) was induced with streptozotocin and hypercholesterolemia (HC) via a high-fat diet in 18 swine (DM + HC), while 16 healthy swine served as controls. After 5 months of follow-up, FVIII activity (FVIII:C) was significantly higher in DM + HC swine (5.85 IU/mL [5.00-6.81]) compared with controls (4.57 [3.76-5.40],
Identifiants
pubmed: 33506473
doi: 10.1055/s-0040-1722185
doi:
Substances chimiques
Biomarkers
0
Factor VIII
9001-27-8
von Willebrand Factor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
676-686Subventions
Organisme : MEDIA-261409
ID : European Commission FP7-Health-2010
Organisme : 81Z0600207
ID : German Center for Cardiovascular Research
Organisme : CVON2014-11
ID : Netherlands CardioVascular Research Initiative: an initiative with support of the Dutch Heart Foundation
Organisme : CVON2016
ID : Netherlands CardioVascular Research Initiative: an initiative with support of the Dutch Heart Foundation
Organisme : 251272
ID : Academy of Finland
Commentaires et corrections
Type : CommentIn
Informations de copyright
Thieme. All rights reserved.
Déclaration de conflit d'intérêts
F.A. received the CSL Behring-Professor Heimburger Award 2018 and a travel grant from Sobi. F.W.G.L. received research support from CSL Behring and Shire/Takeda for performing the WiN study; is a consultant for uniQure, Novo Nordisk, and Shire/Takeda, the fees of which go to the institution; and has received a travel grant from Sobi. He is also a DSMB member for a study by Roche.